News

Video

Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Dr. Alan Skarbnik discusses interim findings from the Phase 3 AMPLIFY trial, highlighting the efficacy and safety of fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, compared to chemoimmunotherapy for treatment-naive chronic lymphocytic leukemia.

Related Videos
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab.
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Guillermo Garcia-Manero, MD